Trial Profile
A Phase II Trial of Transurethral Surgery Followed by a Combination of Atezolizumab (Tecentriq) an Anti-PDL-1 (MPDL3280A) With Trimodal Therapy in Patients With Muscle-Invasive Bladder Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Gemcitabine (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions
- 18 May 2020 Status changed from recruiting to discontinued.as per results presented at the 115th Annual Meeting of the American Urological Association
- 18 May 2020 Results (N=8, between December 2017 and January 2019) presented at the 115th Annual Meeting of the American Urological Association
- 17 Aug 2018 New trial record